Application of NIT2 in Chemosensitizing Agents in Gastric Cancer

By detecting and regulating the expression level of NIT2 in gastric cancer cells and combining specific chemotherapy drugs, the problem of poor chemotherapy effect of gastric cancer is solved, and the sensitivity and prognosis of chemotherapy are significantly improved, providing new therapeutic targets and evaluation methods.

CN118186089BActive Publication Date: 2024-11-12THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410394325.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-02
Publication Date
2024-11-12
Estimated Expiration
2044-04-02

AI Technical Summary

Technical Problem

Among the existing gastric cancer chemotherapy regimens, especially those based on fluorouracil (5FU), the effective efficiency is low and patients are prone to chemotherapy tolerance, resulting in poor treatment effect and poor prognosis, and lack of effective evaluation and improvement methods.

Method used

By detecting the expression level of NIT2 in gastric cancer cells, using NIT2 as an important target to increase or inhibit its expression to improve chemotherapy sensitivity, combined with specific chemotherapy drugs such as 5-FU and metformin (Met), PCR, immunohistochemistry, etc. Methods Assessment of chemotherapy sensitivity and prognosis and develop pharmaceutical compositions and kits containing NIT2 active agents.

Benefits of technology

It significantly improves the sensitivity of gastric cancer chemotherapy, reduces chemotherapy tolerance, provides a scientific basis for evaluating the effect and prognosis of chemotherapy, provides a new direction for individualized treatment, and improves the treatment effect and survival rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118186089B_ABST
    Figure CN118186089B_ABST
Patent Text Reader

Abstract

The present invention discloses the application of NIT2 in increasing the sensitivity of gastric cancer chemotherapy and / or prognosis judgment, and the present invention belongs to the field of pharmaceutical biotechnology. The present invention first discovered the biomarker NIT2 that is positively correlated with the sensitivity of gastric cancer chemotherapy, and judged the chemotherapy resistance and prognosis of gastric cancer patients by detecting the changes of NIT2 in the tumor tissue of gastric cancer patients, and significantly improved the sensitivity of gastric cancer cells to chemotherapy by activating NIT2. The present invention found that NIT2 expression was significantly reduced in gastric cancer tissues through clinical gastric cancer patient specimens, cohort follow-up data and in vivo animal models, and was negatively correlated with the poor prognosis of gastric cancer patients after chemotherapy; at the same time, a series of in vitro and in vivo functional experiments showed that NIT2 promoted the sensitivity of gastric cancer cells to chemotherapeutic drugs, and the ubiquitination site that degraded NIT2 by mutation could significantly improve the chemotherapy efficacy of gastric cancer, and improve the therapeutic effect and prognosis of chemotherapy in gastric cancer patients. The present invention provides new targets and methods for the diagnosis, prognosis and treatment of gastric cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to the application of NIT2 in chemosensitization of gastric cancer. Background Art

[0002] Due to the lack of effective non-invasive diagnostic technology, most gastric cancer patients are already in the middle and late stages of gastric cancer when they are diagnosed, which increases the difficulty of treatment and poor prognosis. At present, the treatment of gastric cancer mainly includes surgical resection, chemotherapy, radiotherapy and targeted therapy. For patients with early gastric cancer, surgical resection is the main treatment method and can achieve good therapeutic effects. For patients with advanced gastric cancer, chemotherapy and radiotherapy can help control the disease, alleviate symptoms, and prolong the survival time of patients. Up to now, the principle of treatment for advanced gastric cancer is comprehensive treatment based on systemic chemotherapy, and its first-line chemotherapy regimen is fluorouracil (5FU) alone or a chemotherapy regimen based on 5FU. As a key basic drug for first-line chemotherapy, the efficacy of 5FU is still low. The poor sensitivity of 5FU chemotherapy has become an important reason for postoperative recurrence and low survival rate in patients with advanced gastric cancer. At present, there are very limited effective ways to improve 5FU resistance. Therefore, screening and identifying key markers that regulate the sensitivity of gastric cancer 5FU chemotherapy and clinical transformation are the key to improving the efficacy of gastric cancer chemotherapy. Summary of the invention

[0003] The purpose of the present invention is to solve the problems in the prior art that gastric cancer patients have poor chemotherapy effects and are prone to chemotherapy resistance, and thus an in-depth study was conducted on the occurrence mechanism of gastric cancer chemotherapy resistance, and it was clarified that NIT2 is an important target related to gastric cancer chemotherapy resistance. The chemotherapy resistance and prognosis of gastric cancer patients can be judged by detecting the expression level of NIT2 in gastric cancer cells, and the chemotherapy sensitivity of gastric cancer can be effectively improved by increasing the expression of NIT2 or inhibiting the degradation of NIT2, providing a scientific basis for the formulation of subsequent treatment plans and prognosis evaluation.

[0004] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0005] The first aspect of the present invention provides the use of NIT2 in the preparation of a product for evaluating the sensitivity of gastric cancer to chemotherapeutic drug treatment and / or the prognosis.

[0006] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0007] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0008] Preferably, the NIT2 expression level is detected to evaluate the sensitivity of gastric cancer to chemotherapy drugs and / or the prognosis.

[0009] Preferably, the detection method is selected from one or more of PCR, immunohistochemistry and Western Blot.

[0010] Preferably, the NIT2 expression level is selected from the NIT2 gene expression level and / or the NIT2 protein expression level.

[0011] Preferably, the NIT2 gene expression level is detected by the following primer pair:

[0012] The upstream primer sequence of the primer pair is shown in SEQ ID NO: 1 (ttgggagtta cttcagcg), and the downstream primer sequence is shown in SEQ ID NO: 2 (ccaggcaacatagg agg).

[0013] Preferably, the NIT2 protein expression level is detected by NIT2 monoclonal antibody and / or NIT2 polyclonal antibody; most preferably, the NIT2 protein expression level is detected by anti-NIT2 antibody, for example, one or more of which can be selected from PA5-49733 (Thermo Fisher Scientific), ab254759 (abcam), and NBP1-89486 (NOVUS).

[0014] The second aspect of the present invention provides the use of NIT2 in the preparation of a product for improving the sensitivity of chemotherapeutic drugs to the treatment of gastric cancer.

[0015] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0016] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0017] The third aspect of the present invention provides the use of a NIT2 active agent in the preparation of a product for improving the sensitivity of chemotherapeutic drugs to the treatment of gastric cancer. The NIT2 active agent is selected from the NIT2-K60R mutant, and its sequence is shown in SEQ ID NO:3.

[0018] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0019] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0020] The fourth aspect of the present invention provides a pharmaceutical composition for treating gastric cancer, comprising one or more of NIT2 nucleotides, NIT2 proteins, NIT2 active agents, and at least one chemotherapeutic drug; the NIT2 active agent is selected from the NIT2-K60R mutant, whose sequence is shown in SE Q ID NO: 3.

[0021] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0022] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0023] A fifth aspect of the present invention provides the use of a reagent for detecting the expression level of NIT2 in the preparation of a product for evaluating the sensitivity of gastric cancer to chemotherapeutic drug treatment and / or the prognosis.

[0024] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0025] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0026] Preferably, the reagent for detecting the expression level of NIT2 includes primers for detecting the expression level of NIT2 gene and / or a reagent for detecting the expression level of NIT2 protein.

[0027] Preferably, the primers for detecting the expression level of the NIT2 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown as SEQ ID NO: 1, and the downstream primer sequence is shown as SEQ ID NO: 2.

[0028] Preferably, the reagent for detecting the expression level of NIT2 protein is selected from NIT2 monoclonal antibody and / or NIT2 polyclonal antibody.

[0029] Preferably, the reagent for detecting the expression level of NIT2 protein is selected from anti-NIT 2 antibodies, for example, one or more selected from PA5-49733 (Thermo Fisher Scientific), ab254759 (abcam), and NBP1-89486 (NOVUS).

[0030] The sixth aspect of the present invention provides a kit for evaluating the sensitivity and / or prognosis of gastric cancer to chemotherapy drugs, comprising a reagent for detecting the expression level of NIT2; and one or more of PCR enzyme, PCR buffer, dNTPs, and fluorescent substrate.

[0031] Preferably, the chemotherapy drug is selected from one or more of anthracycline chemotherapy drugs and benzene ring chemotherapy drugs.

[0032] Preferably, the chemotherapy drug is selected from one or more of fluorouracil (5-FU) and metformin (Met).

[0033] Preferably, the reagent for detecting the expression level of NIT2 includes primers for detecting the expression level of NIT2 gene and / or a reagent for detecting the expression level of NIT2 protein.

[0034] Preferably, the primers for detecting the expression level of the NIT2 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown as SEQ ID NO: 1, and the downstream primer sequence is shown as SEQ ID NO: 2.

[0035] Preferably, the reagent for detecting the expression level of NIT2 protein is selected from NIT2 monoclonal antibody and / or NIT2 polyclonal antibody.

[0036] Preferably, the reagent for detecting the expression level of NIT2 protein is selected from anti-NIT 2 antibodies, for example, one or more selected from PA5-49733 (Thermo Fisher Scientific), ab254759 (abcam), and NBP1-89486 (NOVUS).

[0037] Preferably, the fluorescent substrate is selected from Syber Green or a fluorescently labeled probe.

[0038] It should be understood that, in the context of the present invention, unless otherwise specified, the NIT2 includes NIT2 nucleotides and NIT2 proteins encoded by NIT2 nucleotides and other components; NIT2 activators refer to products that can specifically activate NIT2 function and / or inhibit NIT2 activity loss or degradation, such as the NIT2-K60R mutant exemplified in the present invention, which can inhibit NIT2 degradation by mutating the 60th lysine site of NIT2 to arginine. The NIT2 inhibitor refers to a substance that can specifically downregulate the expression level of NIT2 and / or the transcription level of its mature mRNA and / or the expression level or activity of NIT2 protein, such as antisense oligonucleotides, siRNA, shRNA, sgRNA, antagomiRs, miRNA sponges, miR NAErasers, Target Masking and / or multi-target methods to downregulate the expression level and / or activity of NIT2, as long as the level and / or activity of NIT2 can be reduced. The primers and / or primer pairs refer to PCR primers used to synthesize the cDNA chain of the NIT2 gene in PCR, so as to detect the expression level of the NIT2 gene mRNA. In addition to the primers and / or primer pairs listed in the present invention, those skilled in the art are fully capable of designing corresponding primers and / or primer pairs according to the gene sequence of NIT2 using conventional methods and means in the art including but not limited to molecular biology, and screening the designed primers and / or primer pairs by conventional experimental means, as long as they can achieve specific detection of the NIT2 expression level; conventional antibodies in the art can also be used to detect the expression level of the NIT2 protein.

[0039] Compared with the prior art, the present invention has the following technical effects:

[0040] (1) The present invention found that NIT2 is a gene that is highly correlated with gastric cancer chemotherapy resistance through clinical gastric cancer patient specimens and cohort follow-up data, and its expression level is significantly reduced in gastric cancer tissue. The expression level of NIT2 is significantly negatively correlated with the poor prognosis of gastric cancer patients after chemotherapy, and can be used to predict the tolerance and sensitivity of gastric cancer chemotherapy, providing an early assessment for patients to receive preoperative treatment.

[0041] (2) The present invention has confirmed through a series of in vivo and in vitro experiments that NIT2 can promote the sensitivity of gastric cancer cells to chemotherapeutic drugs. Maintaining or increasing the intracellular NIT2 expression level by promoting NIT2 expression, inhibiting NIT2 degradation or inactivation, etc. can significantly reduce the tolerance of chemotherapeutic drugs to gastric cancer treatment and improve its therapeutic activity. By revealing the correlation between NIT2 and gastric cancer chemotherapy tolerance, the present invention has important practical significance for solving the difficult problems of clinical efficacy differences between individuals and the gaps in regression effects / prognosis assessment, and better realizing precision treatment. It provides a new drug treatment target for humans to conquer gastric cancer, thereby providing a new direction for subsequent drug research and development, clinical treatment, etc., and has extremely high social value and market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Schematic diagram of the results of immunohistochemistry detection of NIT2 expression in gastric cancer patients.

[0043] Figure 2 Schematic diagram of WB detection of NIT2 expression in gastric cancer patients.

[0044] Figure 3 Schematic diagram of the results of immunohistochemical detection of NIT2 expression in tissues of gastric cancer patients who responded or did not respond to 5FU treatment.

[0045] Figure 4 This is a schematic diagram showing the effect of NIT2 expression in tumor tissue of gastric cancer patients on their survival rate.

[0046] Figure 5 This is a schematic diagram of the effect of NIT2 expression in tumor tissue of gastric cancer patients on patient survival rate in the TCGA gastric adenocarcinoma database.

[0047] Figure 6 Schematic diagram of the results of shRNA knockdown efficiency detection of NIT2.

[0048] Figure 7 Schematic diagram of the effect of 5-FU on the activity of NIT2 knockdown gastric cancer cells.

[0049] Figure 8 Schematic diagram of the effect of 5-FU on apoptosis of gastric cancer cells with NIT2 knockdown.

[0050] Fig. 9 Schematic diagram of the effect of 5-FU on the activity of gastric cancer cells overexpressing NIT2.

[0051] Fig.10 Schematic diagram of the results of knocking down NIT2 to detect the growth ability of gastric cancer organoids in response to 5FU.

[0052] Fig.11Schematic diagram of the effect of metformin (Met) combined with 5FU on NIT2 knockdown cell activity.

[0053] Fig.12 Schematic diagram of the effect of the lysine 60 mutant of NIT2 on the killing response of 5-FU. DETAILED DESCRIPTION

[0054] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0055] Unless otherwise specified, the cell lines listed in the context of the present invention, including HEK 293T, MKN45, AGS, etc., are cultured according to the prior art, and all cell lines are identified by short tandem repeat analysis of the China Center for Type Culture Collection (Wuhan), and the presence of mycoplasma contamination is verified using a PCR detection kit (Shanghai Biothrive Sci), and frozen in liquid nitrogen and used for subsequent experiments. The reagents used in the present invention are all commercially available. The experimental methods used in the present invention, such as nucleic acid extraction, whole genome sequencing, primer design, immunohistochemistry, Western blot, cell experiments, etc., are all conventional methods and techniques in the art. Representative results selected from the biological experiment repetitions are presented in the context figures, and the data are displayed as mean±SD and mean±SEM as specified in the figure. All in vitro experiments were repeated at least three times, and animal experiments were repeated twice. The data were analyzed using GraphPad Prism 8.0 or SPSS22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences between two or more groups. p<0.05 is considered to be a significant difference.

[0056] Example 1

[0057] First, biopsy samples of gastric cancer patients from the First Affiliated Hospital of Sun Yat-sen University were selected. The inclusion criteria for patients were as follows: 1) aged 18 years or older (including 18 years old), both male and female. 2) Patients with gastric cancer confirmed by histology or pathology (stage I-IV) receiving fluorouracil drugs alone or in combination with other chemotherapy drugs. 3) Paraffin sections prepared from fresh tumor biopsy tissues were collected. 4) The expected survival period was greater than or equal to 3 months. Then, the expression level of NI T2 in the tumor tissue was detected. The specific steps are as follows:

[0058] (1) The biopsy sample tissue was embedded in paraffin for sealing. The paraffin specimen was stored at room temperature and the cut white slice was stored in a refrigerator at 4°C.

[0059] (2) During the experimental test, take out the paraffin sections and bake them in a 60°C oven for about 2 hours to allow the sections to adhere to the glass slide.

[0060] (3) Dewax the sections in two portions of xylene, each for 10 min.

[0061] (4) The sections were sequentially placed in gradient alcohol (100%, 100%, 95%, 85%, 70%) for hydration treatment, each time for 5-7 minutes, and then washed three times with PBS, each time for 3 minutes.

[0062] (5) Immerse the sections in citrate antigen retrieval solution and heat them in a microwave oven at medium-high temperature for 20 min for antigen retrieval. After heating, let the sections cool naturally to room temperature in the antigen retrieval solution and wash them three times with PBS for 3 min each time.

[0063] (6) Place the slices in a light-proof humidified box, cover the tissue with 3% hydrogen peroxide, and leave at room temperature for 30 minutes to completely remove endogenous peroxidase.

[0064] (7) Wash three times with PBS, 3 min each time. Add blocking solution and block at room temperature for 30 min to reduce nonspecific binding of the primary antibody.

[0065] (8) Shake off the blocking solution, add primary antibody to cover the tissue without washing, and place in a humidified box at 4°C for blocking overnight.

[0066] (9) The next day, the cells were placed at room temperature for 1 h, then washed with PBS for 5 min, and repeated three times.

[0067] (10) Add the reaction sensitization solution and incubate at room temperature for 20 min, then wash three times with PBS; add the biotin-labeled secondary antibody and incubate at room temperature for 30 min, then wash with PBS for 5 min, and repeat three times.

[0068] (11) DAB was added dropwise for color development, and after color development was complete, the reaction was terminated by placing the mixture in water.

[0069] (12) Add hematoxylin for 25-30 seconds for re-staining, and place in water to terminate the staining; then rinse in running water for 30-45 minutes until the color of the section stabilizes for anti-blueing treatment.

[0070] (13) Graded alcohol dehydration: Dehydrate the sections by immersing them in 70%, 85%, 95%, 100%, 100% alcohol, and xylene in sequence for 5 min each time, and then seal the sections.

[0071] Two independent researchers scored the clinical pathological immunohistochemical sections of the patients without knowing the patient information. The staining intensity was graded from 0 to 3: 0: all negative; 1: weak; 2: moderate; 3: strong. Four scores were assigned according to the percentage of positive cells: 0%-25% for 1 point; 26%-50% for 2 points; 51%-75% for 3 points; and above 75% for 4 points. Combining the staining intensity and the proportion score, the total score representing the NIT2 content in the pathological tissue was obtained. The test results are as follows: Figure 1 The results showed that the expression level of NIT2 in gastric cancer tissues of gastric cancer patients was significantly lower than that in normal tissues (***p<0.001).

[0072] Subsequently, Western Blot was used to further verify the expression level of NIT2 in gastric cancer tissues. The specific steps are as follows:

[0073] (1) Gastric cancer cells and normal cells were obtained from gastric cancer tissues and paracancerous tissues, respectively. After culture, they were digested and collected into 1.5 mL EP tubes. The cells were washed twice with PBS, and cell lysis buffer containing 1× protease inhibitors and phosphatase inhibitors was added. The cells were placed on ice for 30 min. After cell lysis, the cells were collected into 1.5 mL EP tubes and centrifuged at 12,000 rpm and 4°C for 10 min.

[0074] (2) After protein quantification, add 5× protein loading buffer according to the sample volume, mix well, and incubate at 95°C in a water bath for 5 min.

[0075] (3) The protein sample obtained in step (2) was subjected to protein electrophoresis with the starting voltage set to 80 V. When the protein marker bands were clearly separated, the voltage was adjusted to 120 V.

[0076] (4) After the protein electrophoresis is completed, the membrane can be transferred. First, the protein gel is placed in the transfer solution for balance, and then an appropriate amount of transfer solution is added to the container. The sponge, filter paper, PVD F membrane (activated with methanol), gel, filter paper, and sponge are placed in order. The gas is removed and the transfer tank is placed in ice water. The transfer condition is 300mA constant current for 1h.

[0077] (5) After the transfer is completed, place the membrane in 5% milk and block it on a shaker at room temperature for 1 hour.

[0078] (6) After blocking, wash the membrane once with 1× TBST buffer, cut the required bands, add the corresponding primary antibody, and place it on a shaker at 4°C overnight.

[0079] (7) Recover the primary antibody and wash the membrane three times with 1× TBST buffer, each time for 10 min.

[0080] (8) Incubate the secondary antibody at room temperature for 1 h, then wash the membrane three times with TBST buffer, 10 min each time.

[0081] (9) After washing the membrane, chemiluminescence can be performed. Prepare the ECL luminescence analyzer (A:B = 1:1) and use a Biorad chemiluminescence analyzer for luminescence development.

[0082] The experimental test results are as follows Figure 2 The results showed that the expression level of NIT2 in gastric cancer tissues was significantly reduced, which was consistent with the results of the above tissue IHC analysis.

[0083] Furthermore, the gastric cancer patients who received 5-FU treatment were divided into a 5-FU-sensitive group and a 5-FU-resistant group according to their sensitivity to 5-FU treatment. Gastric cancer tissue samples from each group were collected and immunohistochemical analysis was performed according to the above method. The results are as follows: Figure 3 The results showed that the expression level of NIT2 in tumor tissues of patients in the 5-FU sensitive group was significantly higher than that in the 5-FU resistant group (***p<0.001), suggesting that the expression level of NIT2 has a key influence on the therapeutic effect of 5-FU.

[0084] The above experiments have shown that NIT2 is lowly expressed in gastric cancer tissues and highly expressed in normal tissues, and the expression level of NIT2 in gastric cancer tissues is positively correlated with the therapeutic activity of 5-FU. In order to clarify the effect of NIT2 on the survival rate of gastric cancer patients, a follow-up analysis of gastric cancer patients after treatment in the First Affiliated Hospital of Sun Yat-sen University found that patients can benefit significantly from high expression of NIT2. The overall survival rate (OS) of patients with high expression of NIT2 in gastric cancer tissues is significantly higher than that of patients with low expression of NIT2 (see Figure 4 ).

[0085] In order to further verify the effect of NIT2 expression level in gastric cancer tissue on patient survival rate, the TCGA gastric adenocarcinoma database was used to divide the tumor cells into NIT2 high expression group and NIT2 low expression group according to the NIT2 expression level in the tumor cells, and their overall survival rates were analyzed. Figure 5 The results showed that, consistent with the analysis results of the above clinical samples, the overall survival rate (OS) of patients with high expression of NIT2 in gastric cancer tissue was significantly higher than that of patients with low expression of NIT2.

[0086] Example 2

[0087] In the above examples, the effect of NIT2 expression level on the survival rate and treatment effect of gastric cancer patients was clearly demonstrated in clinical samples. In order to further study the effect of NIT2 on gastric cancer, a series of in vitro experiments were conducted to further study it.

[0088] First, shRNA was designed to reduce the expression level of NIT2 in cells and its inhibitory activity was verified. The specific steps are as follows:

[0089] (1) Design shRNA knockdown sequences on the Sigma website, design primers based on the shRNA hairpin structure and synthesize primers, dilute the synthesized shRNA primers with water to 100 μM, take 10 μL of the upstream and downstream primers respectively, mix them evenly, and then use a PCR instrument to gradually cool down from 100°C to room temperature to anneal and synthesize double strands; this embodiment uses two shRNAs as examples, namely shNIT2#1 (sequence as shown in SEQ ID NO: 4, which is gcaatcgtgtattcagacata) and shNIT2#2 (sequence as shown in SEQ ID NO: 5, which is acataatcaactcccta ttaa).

[0090] (2) The pLKO.1 lentiviral vector was double-digested with EcoRI and AgeI endonucleases, and two single bands were obtained by gel running after digestion. The larger band was cut out for gel recovery; then the annealed double-stranded DNA was ligated to the vector after gel recovery.

[0091] (3) 293T cells in the logarithmic growth phase were seeded in a 10 cm culture dish at a seeding density of about 70%; 6000 ng of the target plasmid containing shNIT2#1 or shNIT2#1, 4500 ng of PSPAX 2 and 1500 ng of PMD2.G were transfected into the 293T cells and cultured for 48 h.

[0092] (4) After 48 hours, the culture medium was collected and the cell debris was filtered out using a 0.45 μm filter to obtain the virus solution.

[0093] (5) One day before infection, inoculate the gastric cancer cells (MKN45, AGS) in the logarithmic growth phase to be infected into a 6 cm culture dish, discard the original culture medium, add 3 mL of virus solution, and add 3 μL of polybrene to promote virus infection. After 24 hours, discard the virus solution and replace with fresh culture medium to continue culturing.

[0094] (6) 48 hours after infection, the culture medium is discarded and a culture medium containing an appropriate concentration of puromycin is added. At this point, cells that have successfully integrated the exogenous gene have puromycin resistance and can survive. After continuous screening for 7 to 10 days, a stable cell line can be obtained, and the NIT2 expression level can be detected by qPCR or WB to determine whether the knockdown is successful.

[0095] The method for detecting the expression level of NIT2 in gastric cancer cells by WB is the same as that in Example 1; the method for detecting the expression level of NIT2 in gastric cancer cells by qPCR is as follows:

[0096] (1) After washing the gastric cancer cells with PBS, add 1 mL of Trizol to each well and place them horizontally at room temperature for 2 minutes to allow the lysis solution to be evenly distributed on the cell surface and lyse the cells. Use a pipette to blow off the cells, and then transfer the lysis solution to a 1 mL centrifuge tube without RNase.

[0097] (2) Incubate at room temperature for 5 min, centrifuge at 10,000 × g for 15 min at 4°C, aspirate the supernatant, add chloroform, shake vigorously, and incubate at room temperature for 3 min.

[0098] (3) Centrifuge at 10,000 × g for 15 min at 4°C. Carefully aspirate the aqueous phase, add an equal volume of isopropanol, mix well, and incubate at room temperature for 10 min.

[0099] (4) Centrifuge at 4°C and 10,000×g for 10 min, remove the supernatant, and wash with 1 mL of 75% ethanol (prepared with DEPC water).

[0100] (5) Centrifuge at 4°C and 7500×g for 5 min, discard the supernatant, open the lid and dry the precipitate, add 12 μL of DEPC water, incubate at 60°C for 10 min to dissolve the RNA and detect the concentration. Use HiScript II reverse transcriptase (Vazyme#R201-01) to reverse transcribe the total RNA into cDNA, and remove the genomic DNA at the same time. According to the measured RNA concentration, calculate the reaction system, as shown in Table 1 below.

[0101] Table 1 Reverse transcription reaction system

[0102]

[0103] (6) cDNA was diluted at a ratio of 1:5 as a template, and qPCR was performed using ChamQ SYBR qPCR Master Mix (Vazyme #Q712) from Novagen. The 96 / 384-well fluorescence quantitative PCR instrument was Biorad. The reaction system configuration (taking a total volume of 20 μL as an example) was as follows: 2×Taq Pro Universal SYBR qPCR Master Mix 10 μL, upstream primer 0.4 μL, downstream primer 0.4 μL, cDNA 2 μL, ddH2O 7.2 μL; the primer sequences and amplification procedures used are shown in Tables 2 and 3, respectively.

[0104] Table 2 Primer sequences

[0105]

[0106] Table 3 qPCR amplification program

[0107]

[0108] Test results such as Figure 6 The results show that the two shRNAs designed according to the present invention can produce significant inhibitory activity on NIT2 and reduce the expression levels of NIT2 protein and RNA in gastric cancer cells.

[0109] Subsequently, the effect of inhibiting NIT2 expression level on gastric cancer cell proliferation and apoptosis was studied. The specific steps of the cell proliferation experiment are as follows:

[0110] (1) Gastric cancer cells (MKN45 and AGS) transfected with plasmids containing knockdown NIT2 gene expression sequences (shNIT2#1, shNIT2#2) or blank control plasmid (shNT) in the logarithmic growth phase were digested with trypsin and counted. The appropriate cell density (1.5×10 5 / well) and inoculated into 96-well plates (3 replicates).

[0111] (2) The cells were cultured in a 37°C incubator and collected at 12 h, 24 h, 36 h, and 48 h. 10 μL of CCK-8 was added to each well. The culture plate was incubated in the incubator for 1-4 h, and the absorbance at 450 nm was measured to evaluate the cell proliferation. A parallel experimental group was set up, except that each group of cells was treated with the same concentration of 5-FU (50 μM), and cell culture and absorbance detection were performed in the same manner.

[0112] The experimental results are as follows Figure 7 The results showed that after the expression of NIT2 in cells was inhibited by shNIT2, there was almost no effect on the viability of gastric cancer cells; however, when treated with the same concentration of 5-FU, the cell survival rate of the blank control plasmid (shNT) group was significantly lower than that of the shNIT2 treatment group (***p < 0.001), indicating that the expression level of NIT2 in cells is closely related to the cytotoxicity of 5-FU. The higher the expression level of NIT2, the more significant the killing effect of 5-FU on gastric cancer cells.

[0113] The specific steps of the cell apoptosis experiment are as follows:

[0114] (1) Gastric cancer cells (MKN45 and AGS) transfected with plasmids containing knockdown NIT2 gene expression sequences (shNIT2#1, shNIT2#2) or blank control plasmids (shNT) in the logarithmic growth phase were digested with trypsin and counted. The appropriate cell density (1.5×105 / well) and inoculated into 12-well plates (3 replicates). Another parallel experimental group was set up, the difference being that each group of cells was treated with the same concentration of 5-FU (50 μM).

[0115] (2) Cultured in a 37°C incubator, cells were collected in 10 mL centrifuge tubes after 48 h, and the number of cells per sample was 1-5×10 5 / mL, centrifuge at 4°C, 1800 rpm for 5 min, and discard the culture medium.

[0116] (3) Wash twice with pre-cooled PBS buffer, centrifuge at 4°C, 1800 rpm for 5 min; resuspend the cells with 100 μL of 1× Binding Buffer and gently blow until a single-cell suspension is obtained.

[0117] (4) Add 5 μL Annexin V-FITC and 5 μL PI Staining Solution and gently blow to mix; incubate at room temperature for 10 min in a dark place, then add 400 μL 1× Binding Buffer, gently mix, and detect using a flow cytometer.

[0118] The experimental results are as follows Figure 8 The results showed that under the condition of 5FU treatment, after silencing the NIT2 gene by shRNA, the apoptosis level of MKN45 and AGS cells was significantly weakened, and the reduction of NIT2 expression level could significantly promote the growth of gastric cancer cells and inhibit cell apoptosis, which significantly reduced the apoptosis rate of MKN45 and AGS cells, and the difference was statistically significant (***p < 0.001), indicating that the level of NIT2 in cells affects the apoptosis-inducing effect of 5-FU on gastric cancer cells, and the high expression of NIT2 helps to promote the apoptosis of gastric cancer cells by 5-FU.

[0119] Furthermore, Flag-NIT2 was transfected into gastric cancer cells (MKN45, AGS) according to the above method to overexpress NIT2, and the above WB and PCR methods were used to detect and verify the overexpression effect of NIT2 protein and RNA in the cells. Subsequently, the constructed NIT2 overexpressing cells were taken to repeat the above cell proliferation experiment, and the results were as follows Fig. 9 The results showed that under 5FU treatment, compared with the vector group (Vector), intracellular NIT2 overexpression could significantly inhibit the proliferation activity of gastric cancer cells and effectively increase the killing effect of 5-FU on cells (***p < 0.001).

[0120] Example 3

[0121] According to the method in the above example, shRNA was used to construct a NIT2 knockout plasmid to detect the response of NIT2 expression level to the growth ability of gastric cancer organoids to 5-FU. The specific steps are as follows:

[0122] (1) Gastric cancer tumor tissues from gastric cancer patients were dissociated into cell clusters using mechanical and enzymatic methods and then cultured in a hydrogel with ECM components under appropriate culture conditions.

[0123] (2) These patient-derived organoids were transfected with the constructed lentivirus loaded with shNT or shNIT2.

[0124] (3) Organoids were seeded into 96-well plates and treated with 5-FU every 2 days after 6 days.

[0125] (4) According to The proliferation rate was determined according to the instructions of the luminescent cell viability detection kit (Promega).

[0126] Test results such as Fig.10 The results showed that knocking down NIT2 using shRNA had no effect on the proliferation of gastric cancer tissue. When treated with 5-FU, gastric cancer tissue cells with knocked down NIT2 could effectively survive compared with the control gastric cancer tissue.

[0127] Existing studies have shown that metformin (Met) can block the energy supply of gastric cancer cells by inhibiting oxidative phosphorylation and induce apoptosis of gastric cancer cells. Under the action of metformin, gastric cancer cells show dose-dependent inhibition of oxidative phosphorylation signals. In this regard, metformin (Met) and / or 5-FU were used as active ingredients to treat gastric cancer cells loaded with shNIT2 (shNIT2#1) to detect the effect of intracellular NIT2 levels on the chemotherapy effect. The results are as follows Fig.11 As shown, it is consistent with the above results, that is, under the condition of 5FU treatment, the inhibition of intracellular NIT2 expression by shNIT2 can significantly improve the vitality of gastric cancer cells; at the same time, under the condition of 5-FU, Met or 5-FU+Met treatment, the cell survival rate of the blank control plasmid (shNT) group was significantly lower than that of the shNIT2 treatment group (***p<0.001), indicating that the expression level of intracellular NIT2 is positively correlated with the cytotoxicity of chemotherapeutic drugs, the higher the NIT2 expression level, the more significant the killing effect of chemotherapeutics such as 5-FU and Met on gastric cancer cells, and the combined use of 5-FU and Met can produce synergistic gastric cancer cell inhibitory activity.

[0128] In addition, the present invention found that the 60th lysine site of NIT2 can promote the degradation of NIT2 protein. To this end, a mutant of the 60th lysine site of NIT2 is constructed to inhibit the degradation of NIT2, thereby maintaining or improving its expression level in cells. The specific steps are as follows:

[0129] (1) Design primers: Since the homologous recombination method requires the vector to be linearized, two efficient restriction sites in the vector single cloning site can be selected to design primers. Generally, the upstream primer is: 15 bp before the upstream restriction site + 6 bp of the restriction site + 5' target gene sequence, and the downstream primer is: 15 bp after the downstream restriction site (reverse complement) + restriction site + 3' target gene sequence (reverse complement); Lysine at position 60 of NIT2 is mutated to arginine sequence (SEQ ID 3). The specific amplification primer sequences are shown in Table 3 below.

[0130] Table 3 Amplification primer sequences

[0131]

[0132]

[0133] (2) Amplification of target gene fragments: The target gene was amplified by PCR using a high-fidelity PCR polymerase, KOD-Plus-Neo enzyme (TOYOBO, #KOD-401). The PCR reaction system was as follows; PCR conditions were: 94°C pre-denaturation for 2 min, 38 amplification cycles (98°C denaturation for 10 s, Tm°C annealing for 30 s, 68°C extension for 30 s / kb), and 68°C renaturation for 10 min.

[0134] (3) Enzyme digestion of vector: 1 μg of vector and target gene were taken for double enzyme digestion reaction. The enzyme digestion system is as follows. After the reaction system is prepared, it is placed in a 37°C water bath for enzyme digestion. The enzyme digestion reaction system is shown in Table 4 below.

[0135] Table 4 Enzyme digestion reaction system

[0136] Element volume <![CDATA[ddH2O]]> (25-X)μL 10×Buffer 3μL Endonuclease I 1μL Endonuclease II 1μL DNA X = 1000 / concentration μL Total volume 30μL

[0137] (4) Homologous recombination reaction, transformation, colony PCR identification and sequencing identification, the sequence of the constructed NIT2 lysine 60 site mutant (NIT2-K60R) is shown in SEQ ID NO: 3. The homologous recombination reaction system is shown in Table 5 below.

[0138] Table 5 Homologous recombination reaction system

[0139]

[0140]

[0141] Subsequently, the above gastric cancer cell proliferation experiment was repeated using the constructed NIT2-K60R mutant and shNIT2. Fig.12 The results showed that after shNIT2 treatment under 5FU treatment conditions to reduce the expression level of NIT2 in cells and restore the expression of NIT2 wild type (rNIT2-WT), the proliferation activity of cells can be significantly improved, which is consistent with the above experiments; for gastric cancer cells that restore the expression of NIT2-K60R mutant, the degradation of intracellular NIT2 can be effectively inhibited, the intracellular NIT2 level can be maintained, and the proliferation activity of gastric cancer cells can be significantly inhibited (***p < 0.001).

[0142] From the above, it can be clearly seen that NIT2 is a gene that is extremely related to resistance to chemotherapy in gastric cancer. The lower expression level of NIT2 has a significant positive correlation with poor prognosis, which can be used to predict the tolerance and sensitivity of gastric cancer chemotherapy, and provide an early assessment for patients to receive preoperative treatment. At the same time, NIT2 and active ingredients targeting NIT2 have the important function of sensitizing gastric cancer chemotherapy. Accordingly, the expression level of NIT2 in the body can be increased to reduce the patient's tolerance to gastric cancer chemotherapy and improve the therapeutic effect of chemotherapy. The present invention reveals the correlation between the NIT2 gene and gastric cancer chemotherapy tolerance, which has important practical significance for solving the problem of clinical efficacy differences between individuals and the gaps in the regression effect / prognosis assessment, and better realizing precision treatment. It provides a new drug treatment target for humans to conquer gastric cancer, thereby providing a new direction for subsequent drug development, clinical treatment, etc., and has extremely high social value and market application prospects.

[0143] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Use of a reagent for detecting NIT2 expression levels in the preparation of a product for evaluating the sensitivity and / or prognosis of gastric cancer to chemotherapy drugs, It is characterized in that The NIT2 expression level is detected to evaluate the sensitivity of gastric cancer to chemotherapy drugs and / or the prognosis; the chemotherapy drugs are selected from one or more of fluorouracil and metformin.

2. Application of NIT2 active agent in the preparation of products for improving the sensitivity of chemotherapy drugs to gastric cancer treatment, It is characterized in that The NIT2 active agent is selected from the NIT2-K60R mutant, and its nucleotide sequence is shown in SEQ ID NO: 3; the chemotherapy drug is selected from one or more of fluorouracil and metformin.